Clinical impact of antibody formation to botulinum toxin A in children
- 26 April 2004
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 55 (5) , 732-735
- https://doi.org/10.1002/ana.20098
Abstract
We studied the clinical impact of neutralizing antibodies to botulinum toxin A that occurred during long‐term treatment of children between 1993 and 2001. Antibodies were found in high titers in 35 of 110 (31.8%) samples from individual patients. Antibody formation correlated with secondary nonresponse (p < 0.001). The most significant risk factors for antibody formation were the frequency of treatments (p = 0.0001) and the injection of a higher weight‐adapted maximum dose per treatment (p = 0.001).Keywords
Funding Information
- PharmAllergan GmbH, Ettlingen, Germany
- Merz Pharmaceuticals
- Ipsen Pharma
This publication has 14 references indexed in Scilit:
- Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double‐blind, placebo‐controlled, dose‐ranging studyDevelopmental Medicine and Child Neurology, 2002
- Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a StrokeNew England Journal of Medicine, 2002
- Botulinum Toxin Type A Neuromuscular Blockade in the Treatment of Equinus Foot Deformity in Cerebral Palsy: A Multicenter, Open-Label Clinical TrialPediatrics, 2001
- Secondary Non-Response due to Development of Neutralising Antibodies to Botulinum Toxin A during Treatment of Children with Cerebral PalsyNeuropediatrics, 2000
- Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequencyZeitschrift für Neurologie, 1999
- Response and immunoresistance to botulinum toxin injectionsNeurology, 1995
- Development of resistance to botulinum toxin type A in patients with torticollisMovement Disorders, 1994
- Validity of Goal Attainment Scaling in Infants With Motor DelaysPTJ: Physical Therapy & Rehabilitation Journal, 1993
- Botulinum antibodies in dystonic patients treated with type A botulinum toxinNeurology, 1993
- DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLISThe Lancet, 1986